Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Veklury (remdesivir by Year
Veklury (remdesivir — COVID-19 antiviral) — Worldwide YoY growth (%) (%)
Gilead Sciences Veklury (remdesivir: -49.0% in FY2025, down 31.0 pts from a year earlier.
Latest, FY2025
-49.0%
Period ended Dec 31, 2025
Change on a year earlier
-31.0 pts
-18.0% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Veklury | 212 | 337 | (37)% | 911 | 1,799 | (49)%”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Reported in Form 8-K Total Revenue Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Veklury (remdesivir — COVID-19 antiviral) — Worldwide YoY growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -49.0% | -31.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | -18.0% | +26.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2023 | Dec 31, 2023 | -44.0% | -14.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | -30.0% | -128.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| FY2021 | Dec 31, 2021 | 98.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Veklury (remdesivir (%), annual FY2021–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/veklury-total-yoy
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.